Amantadine ( DrugBank: Amantadine )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	57
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	6
127	前頭側頭葉変性症	1

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 10 of 57 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04387773 (ClinicalTrials.gov)	November 5, 2020	11/5/2020	Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease	Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease	Parkinson Disease	Drug: GOCOVRI	Oregon Health and Science University	Adamas Pharmaceuticals, Inc.	Recruiting	50 Years	80 Years	All	12	Phase 4	United States
2	NCT04260581 (ClinicalTrials.gov)	March 1, 2020	5/2/2020	Is Long-term Use of Amantadine Effective in PD?	Is Long-term Use of Amantadine Effective in Parkinson Disease?	Parkinson Disease	Drug: Determination of drug effects through amantadine cessation	Seoul National University Hospital	NULL	Not yet recruiting	40 Years	N/A	All	32	N/A	Korea, Republic of
3	EUCTR2017-002426-20-FR (EUCTR)	05/04/2019	26/11/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descripti ...	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	177	Phase 4	France;Spain;Austria
4	EUCTR2017-002426-20-IT (EUCTR)	21/02/2019	07/10/2020	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON phase, expe ...	Trade Name: Xadago Product Name: Xadago Product Code: [-] INN or Proposed INN: SAFINAMIDE METANSOLFONAT ...	ZAMBON SPA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	France;Spain;Austria;Germany;Italy
5	EUCTR2017-002426-20-AT (EUCTR)	22/01/2019	03/12/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descripti ...	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	105	Phase 4	Spain;Austria
6	EUCTR2017-002426-20-ES (EUCTR)	19/10/2018	20/08/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descripti ...	Zambon SpA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	Spain
7	NCT02589340 (ClinicalTrials.gov)	January 2016	23/10/2015	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Parkinson's Disease;Dyskinesias;Movement Disorders	Drug: Buspirone;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Terminated	18 Years	99 Years	All	6	Phase 1	United States
8	EUCTR2014-003738-24-AT (EUCTR)	26/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movem ...	ADS-5102 (AmantadineHCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 17.1;L ...	Product Name: AmantadineHCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	72	Phase 3	Germany;Spain;Austria;United States
9	EUCTR2014-003739-20-AT (EUCTR)	19/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkin ...	Open-Label Safety Study of ADS-5102 (AmantadineHCl) Extended Release Capsules for the Treatment of L ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;L ...	Product Name: AmantadineHCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Phase 3	United States;Spain;Austria;Germany
10	EUCTR2014-003739-20-DE (EUCTR)	23/04/2015	21/01/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkin ...	Open-Label Safety Study of ADS-5102 (AmantadineHCl) Extended Release Capsules for the Treatment of L ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;L ...	Product Name: AmantadineHCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Spain;Austria;Germany

First Previous1 2 3 4 5 6Next Last

先頭へ

8. ハンチントン病

臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00001930 (ClinicalTrials.gov)	April 1999	3/11/1999	Treatment of Huntington's Chorea With Amantadine	NMDA-Receptor Blockade in Huntington's Chorea	Chorea;Huntington's Disease	Drug: Amantadine	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	25	Phase 2	United States

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03567057 (ClinicalTrials.gov)	July 18, 2018	22/5/2018	A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 AmantadineExtended Release Capsules ...	Multiple Sclerosis;Walking Impairment	Drug: ADS-5102, 274 mg	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	424	Phase 3	United States;Canada
2	NCT03436199 (ClinicalTrials.gov)	March 29, 2018	12/2/2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and ...	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	558	Phase 3	United States;Canada
3	NCT03185065 (ClinicalTrials.gov)	October 4, 2017	9/6/2017	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Completed	18 Years	N/A	All	141	Phase 3	United States
4	NCT02471222 (ClinicalTrials.gov)	May 2015	11/6/2015	Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	Safety and Efficacy of ADS-5102 (AmantadineHCl) Extended Release Capsules in Patients With Multiple ...	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	60	Phase 2	United States
5	EUCTR2012-003418-15-AT (EUCTR)	23/10/2012	09/11/2012	Methylphenidate modified release as treatment of MS-associated fatigue.	Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center rando ...	Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic ap ...	Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg INN or Propo ...	Medizinische Universität Wien	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria
6	EUCTR2010-023678-38-IT (EUCTR)	20/04/2011	02/02/2011	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclero ...	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclero ...	patients with multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10028245	Trade Name: MANTADAN*20CPR 100MG INN or Proposed INN: Amantadine Trade Name: AMPYRA INN or Proposed INN ...	FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR	NULL	Not Recruiting			Female: yes Male: yes			Italy

First Previous1Next Last

先頭へ

127. 前頭側頭葉変性症

臨床試験数 : 89 / 薬物数 : 104 - (DrugBank : 33) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 117

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00127114 (ClinicalTrials.gov)	September 2005	3/8/2005	Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)	Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)	Dementia	Drug: Amantadine;Drug: Placebo	Johns Hopkins University	NULL	Withdrawn	40 Years	90 Years	All	0	Phase 4	United States

First Previous1Next Last

先頭へ